{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:55:23Z","timestamp":1781564123430,"version":"3.54.5"},"reference-count":143,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21NS114764-01A1"],"award-info":[{"award-number":["1R21NS114764-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS100610"],"award-info":[{"award-number":["U01NS100610"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R25NS098999"],"award-info":[{"award-number":["R25NS098999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5U01NS112010 \/807,745"],"award-info":[{"award-number":["5U01NS112010 \/807,745"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2 P30 AG062429-06"],"award-info":[{"award-number":["2 P30 AG062429-06"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AG063911-1"],"award-info":[{"award-number":["U19 AG063911-1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032121","name":"Lundbeck USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032121","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ncl.2024.12.006","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:08:54Z","timestamp":1737533334000},"page":"249-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Atypical Parkinsonian Disorders"],"prefix":"10.1016","volume":"43","author":[{"given":"Nahid","family":"Olfati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh H.","family":"Akhoundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Litvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2024.12.006_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.571800","article-title":"Clinical features of patients with progressive supranuclear palsy in an US insurance claims database","volume":"12","author":"Viscidi","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2024.12.006_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.parkreldis.2021.07.007","article-title":"Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank","volume":"89","author":"Koga","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","article-title":"When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients","volume":"85","author":"Koga","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1212\/WNL.0000000000002350","article-title":"Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis","volume":"86","author":"Rizzo","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s40478-021-01282-8","article-title":"High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease","volume":"9","author":"Russo","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/jnnp.60.6.615","article-title":"Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study","volume":"60","author":"Litvan","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mds.22977","article-title":"What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?","volume":"25","author":"Williams","year":"2010","journal-title":"Mov Disord"},{"issue":"Pt 2","key":"10.1016\/j.ncl.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/brain\/awm301","article-title":"Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy","volume":"131","author":"Ahmed","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.64.2.184","article-title":"Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination","volume":"64","author":"Wenning","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/1533317510391239","article-title":"Extrapyramidal signs in the primary progressive aphasias","volume":"26","author":"Kremen","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.ncl.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jns.2016.11.033","article-title":"Clinical characteristics of parkinsonism in frontotemporal dementia according to subtypes","volume":"372","author":"Park","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib12","first-page":"1375","article-title":"The natural history of primary progressive aphasia: beyond aphasia","volume":"269","author":"Ulugut","year":"2022","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2007.05.049","article-title":"Extrapyramidal symptoms in Frontotemporal Dementia: prevalence and clinical correlations","volume":"422","author":"Padovani","year":"2007","journal-title":"Neurosci Lett"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ana.20873","article-title":"Frontotemporal dementia: clinicopathological correlations","volume":"59","author":"Forman","year":"2006","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","article-title":"Natural history of multiple system atrophy in the USA: a prospective cohort study","volume":"14","author":"Low","year":"2015","journal-title":"Lancet Neurol"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.006_bib16","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/mds.21698","article-title":"Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy","volume":"22","author":"Williams","year":"2007","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.006_bib17","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1093\/brain\/awx254","article-title":"Clinicopathological correlations in behavioural variant frontotemporal dementia","volume":"140","author":"Perry","year":"2017","journal-title":"Brain"},{"issue":"Pt 6","key":"10.1016\/j.ncl.2024.12.006_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: richardson's syndrome and PSP-parkinsonism","volume":"128","author":"Williams","year":"2005","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.55.7.957","article-title":"Clinical presentation and pharmacological therapy in corticobasal degeneration","volume":"55","author":"Kompoliti","year":"1998","journal-title":"Arch Neurol"},{"issue":"14","key":"10.1016\/j.ncl.2024.12.006_bib20","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek","year":"2014","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib21","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mds.10171","article-title":"Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease","volume":"17","author":"Tison","year":"2002","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib22","article-title":"Tremor in multiple system atrophy - a review","volume":"3doi","author":"Kaindlstorfer","year":"2013","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib23","first-page":"104","article-title":"Neuro-ophthalmic findings in progressive supranuclear palsy","volume":"12","author":"Friedman","year":"1992","journal-title":"J\u00a0Clin Neuro Ophthalmol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cxo.12429","article-title":"Visual signs and symptoms of corticobasal degeneration","volume":"99","author":"Armstrong","year":"2016","journal-title":"Clin Exp Optom"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib25","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mds.21999","article-title":"Oculomotor function in multiple system atrophy: clinical and laboratory features in 30 patients","volume":"23","author":"Anderson","year":"2008","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/jnnp.54.7.599","article-title":"Square wave jerks in parkinsonian syndromes","volume":"54","author":"Rascol","year":"1991","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000341621","article-title":"Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor","volume":"68","author":"Rana","year":"2012","journal-title":"Eur Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1212\/01.WNL.0000052686.97625.27","article-title":"Progression of gait, speech and swallowing deficits in progressive supranuclear palsy","volume":"60","author":"Goetz","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archneur.58.2.259","article-title":"Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders","volume":"58","author":"Muller","year":"2001","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/jamaneurol.2016.0412","article-title":"Features of patients with nonfluent\/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration","volume":"73","author":"Santos-Santos","year":"2016","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.006_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/mds.21992","article-title":"Red flags for multiple system atrophy","volume":"23","author":"Kollensperger","year":"2008","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1044\/jshd.4301.47","article-title":"Frequency and cooccurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients","volume":"43","author":"Logemann","year":"1978","journal-title":"J\u00a0Speech Hear Disord"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib33","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/WNL.48.6.1654","article-title":"Characterizing swallowing abnormalities in progressive supranuclear palsy","volume":"48","author":"Litvan","year":"1997","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.006_bib34","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.parkreldis.2015.09.043","article-title":"Swallowing disturbances in the corticobasal syndrome","volume":"21","author":"Grunho","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.006_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16370","article-title":"Dysphagia in primary progressive aphasia: clinical predictors and neuroanatomical basis","volume":"31","author":"Mazzeo","year":"2024","journal-title":"Eur J Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.006_bib36","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00702-010-0563-8","article-title":"In\u00a0vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism","volume":"118","author":"Srulijes","year":"2011","journal-title":"J\u00a0Neural Transm (Vienna)"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1590\/S0004-282X2008000600004","article-title":"Clinical features of dystonia in atypical parkinsonism","volume":"66","author":"Godeiro-Junior","year":"2008","journal-title":"Arq Neuropsiquiatr"},{"issue":"Pt 5","key":"10.1016\/j.ncl.2024.12.006_bib38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/brain\/117.5.1183","article-title":"Corticobasal degeneration. A clinical study of 36 cases","volume":"117","author":"Rinne","year":"1994","journal-title":"Brain"},{"issue":"Suppl 7","key":"10.1016\/j.ncl.2024.12.006_bib39","first-page":"VII7","article-title":"Dystonia in Parkinson's disease","volume":"253","author":"Tolosa","year":"2006","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0034-1381736","article-title":"Progressive supranuclear palsy","volume":"34","author":"Golbe","year":"2014","journal-title":"Semin Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib41","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mds.10234","article-title":"Freezing of gait in postmortem-confirmed atypical parkinsonism","volume":"17","author":"Muller","year":"2002","journal-title":"Mov Disord"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib42","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jamaneurol.2014.753","article-title":"Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease","volume":"71","author":"Perez-Lloret","year":"2014","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/arclin\/acs098","article-title":"Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy","volume":"28","author":"Gerstenecker","year":"2013","journal-title":"Arch Clin Neuropsychol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2012-303618","article-title":"The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders","volume":"84","author":"Rittman","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2024.12.006_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/B978-0-12-823384-9.00016-5","article-title":"Clinical and neuroimaging characteristics of primary progressive aphasia","volume":"185","author":"Tippett","year":"2022","journal-title":"Handb Clin Neurol"},{"issue":"1074","key":"10.1016\/j.ncl.2024.12.006_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/postgradmedj-2015-133247","article-title":"Cognitive impairment in Parkinson's disease","volume":"91","author":"Cosgrove","year":"2015","journal-title":"Postgrad Med J"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib47","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.psychres.2013.08.045","article-title":"Behavioral abnormalities in progressive supranuclear palsy","volume":"210","author":"Gerstenecker","year":"2013","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00702-023-02591-z","article-title":"Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes","volume":"130","author":"Campagnolo","year":"2023","journal-title":"J\u00a0Neural Transm (Vienna)"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/arclin\/acx093","article-title":"The neuropsychology (broadly conceived) of multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration","volume":"32","author":"Gerstenecker","year":"2017","journal-title":"Arch Clin Neuropsychol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib50","first-page":"217","article-title":"Apathy in drug-naive patients with incident Parkinson's disease: the Norwegian ParkWest study","volume":"257","author":"Pedersen","year":"2010","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib51","first-page":"109","article-title":"Autonomic dysfunction in progressive supranuclear palsy","volume":"270","author":"Baschieri","year":"2023","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10286-017-0500-0","article-title":"First symptoms in multiple system atrophy","volume":"28","author":"McKay","year":"2018","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ncl.2024.12.006_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.parkreldis.2021.11.002","article-title":"Neurogenic orthostatic hypotension in early stage Parkinson's disease: new insights from the first 105 patients of the BoProPark study","volume":"93","author":"Baschieri","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2024.103173","article-title":"Longitudinal prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative (PPMI) cohort","volume":"253","author":"Beach","year":"2024","journal-title":"Auton Neurosci"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10286-017-0480-0","article-title":"Urological dysfunction in synucleinopathies: epidemiology, pathophysiology and management","volume":"28","author":"Sakakibara","year":"2018","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ncl.2024.12.006_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104700","article-title":"Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment","volume":"134","author":"Chen","year":"2020","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ncl.2024.12.006_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.995850","article-title":"Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson's disease: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib58","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1212\/WNL.0000000000010002","article-title":"Predicting phenoconversion in pure autonomic failure","volume":"95","author":"Coon","year":"2020","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib59","first-page":"983","article-title":"Evolution of prodromal multiple system atrophy from REM sleep behavior disorder: a descriptive study","volume":"12","author":"Postuma","year":"2022","journal-title":"J\u00a0Parkinsons Dis"},{"issue":"15","key":"10.1016\/j.ncl.2024.12.006_bib60","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/mds.21578","article-title":"Levodopa responsiveness in disorders with parkinsonism: a review of the literature","volume":"22","author":"Constantinescu","year":"2007","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib61","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/mds.28406","article-title":"Is levodopa response a valid indicator of Parkinson's disease?","volume":"36","author":"Martin","year":"2021","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib62","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mds.870120203","article-title":"Multiple system atrophy: a review of 203 pathologically proven cases","volume":"12","author":"Wenning","year":"1997","journal-title":"Mov Disord"},{"issue":"Suppl 12","key":"10.1016\/j.ncl.2024.12.006_bib63","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1002\/mds.20543","article-title":"Therapeutic strategies in multiple system atrophy","volume":"20","author":"Wenning","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.parkreldis.2018.07.016","article-title":"A\u00a0new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease","volume":"54","author":"Quattrone","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib65","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mds.28992","article-title":"Development and validation of automated magnetic resonance parkinsonism index 2.0 to distinguish progressive supranuclear palsy-parkinsonism from Parkinson's disease","volume":"37","author":"Quattrone","year":"2022","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib66","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/S2589-7500(19)30105-0","article-title":"Development and validation of the automated imaging differentiation in parkinsonism (aid-P): a multi-site machine learning study","volume":"1","author":"Archer","year":"2019","journal-title":"Lancet Digit Health"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.006_bib67","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/mds.28672","article-title":"Clinical utility of (18) F-APN-1607 tau PET imaging in patients with progressive supranuclear palsy","volume":"36","author":"Li","year":"2021","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00259-022-06104-0","article-title":"(18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy","volume":"50","author":"Liu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae075","article-title":"In\u00a0vivo PET classification of tau pathologies in patients with frontotemporal dementia","volume":"6","author":"Kubota","year":"2024","journal-title":"Brain Commun"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.006_bib70","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","article-title":"Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy","volume":"77","author":"Brendel","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2024.12.006_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2022.11.018","article-title":"Performance of [(18)F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy","volume":"106","author":"Oliveira Hauer","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"supplement 2","key":"10.1016\/j.ncl.2024.12.006_bib72","article-title":"Evaluation of [3H]OXD-2314 for guiding first-in-human imaging in non-Alzheimer's disease tauopathies","volume":"65","author":"Murrell","year":"2024","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib73","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1212\/CPJ.0000000000001116","article-title":"CSF and circulating NfL as biomarkers for the discrimination of Parkinson disease from atypical parkinsonian syndromes: meta-analysis","volume":"11","author":"Angelopoulou","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.006_bib74","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.ncl.2024.12.006_bib75","first-page":"4248","article-title":"Diagnostic and prognostic performance of plasma neurofilament light chain in multiple system atrophy: a cross-sectional and longitudinal study","volume":"270","author":"Peng","year":"2023","journal-title":"J\u00a0Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.006_bib76","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A\u00a0panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2024.12.006_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-02075-9","article-title":"CSF tau microtubule-binding region identifies pathological changes in primary tauopathies","author":"Horie","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib78","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209585","article-title":"CSF proteomics in patients with progressive supranuclear palsy","volume":"103","author":"Wise","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.006_bib79","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1212\/WNL.0000000000008053","article-title":"Urodynamic study for distinguishing multiple system atrophy from Parkinson disease","volume":"93","author":"Shin","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib80","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.parkreldis.2014.12.003","article-title":"Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson's disease","volume":"21","author":"Kim","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib81","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.parkreldis.2012.01.009","article-title":"123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis","volume":"18","author":"Orimo","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mdc3.13710","article-title":"Alpha-synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid-A systematic review and meta-analysis","volume":"10","author":"Grossauer","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awab431","article-title":"Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies","volume":"145","author":"Poggiolini","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2024.12.006_bib84","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.2381","article-title":"Limitations of the alpha-synuclein seed amplification assay in clinical practice: understanding the pathological diversity of Parkinson syndrome","author":"Morris","year":"2024","journal-title":"JAMA Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.006_bib85","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1111\/ene.16041","article-title":"Comparison of biospecimens for alpha-synuclein seed amplification assays in Parkinson's disease: a systematic review and network meta-analysis","volume":"30","author":"Zheng","year":"2023","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib86","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","article-title":"4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration","volume":"139","author":"Saijo","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib87","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mdc3.13489","article-title":"Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome","volume":"9","author":"Swallow","year":"2022","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2024.12.006_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120614","article-title":"Clinical milestones as triggers for palliative care intervention in progressive Supranuclear palsy and multiple system atrophy","volume":"448","author":"Bessemer","year":"2023","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib89","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/archneur.65.4.460","article-title":"Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN)","volume":"65","author":"Boeve","year":"2008","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib90","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1212\/WNL.38.7.1031","article-title":"Prevalence and natural history of progressive supranuclear palsy","volume":"38","author":"Golbe","year":"1988","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ng.859","article-title":"Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy","volume":"43","author":"Hoglinger","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13024-018-0270-8","article-title":"Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases","volume":"13","author":"Chen","year":"2018","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib93","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13024-018-0267-3","article-title":"Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci","volume":"13","author":"Sanchez-Contreras","year":"2018","journal-title":"Mol Neurodegener"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00005072-199601000-00010","article-title":"Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders","volume":"55","author":"Litvan","year":"1996","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00401-020-02158-2","article-title":"Distribution patterns of tau pathology in progressive supranuclear palsy","volume":"140","author":"Kovacs","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib96","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jnen\/nlad025","article-title":"Low clinical sensitivity and unexpectedly high incidence for neuropathologically diagnosed progressive supranuclear palsy","volume":"82","author":"Driver-Dunckley","year":"2023","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.ncl.2024.12.006_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.117293","article-title":"Disease course and treatment patterns in progressive supranuclear palsy: a real-world study","volume":"421","author":"Morgan","year":"2021","journal-title":"J\u00a0Neurol Sci"},{"issue":"10","key":"10.1016\/j.ncl.2024.12.006_bib98","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1136\/jnnp.2003.027367","article-title":"Abnormalities of optokinetic nystagmus in progressive supranuclear palsy","volume":"75","author":"Garbutt","year":"2004","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop","volume":"47","author":"Litvan","year":"1996","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/mdc3.13413","article-title":"Eye movement disorders in movement disorders","volume":"9","author":"Kassavetis","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib101","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410020509","article-title":"The ocular motor defects in progressive supranuclear palsy","volume":"2","author":"Troost","year":"1977","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib102","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/mds.20347","article-title":"Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes","volume":"20","author":"Wielinski","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-7091-6641-3_6","article-title":"Cognitive disturbances in progressive supranuclear palsy","volume":"42","author":"Litvan","year":"1994","journal-title":"J\u00a0Neural Transm Suppl"},{"key":"10.1016\/j.ncl.2024.12.006_bib104","article-title":"Clinical spectrum of tauopathies","volume":"13","author":"Olfati","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.ncl.2024.12.006_bib105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.parkreldis.2019.07.010","article-title":"Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability","volume":"66","author":"Shoeibi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib106","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","article-title":"Diagnosis across the spectrum of progressive supranuclear palsy and corticobasal syndrome","volume":"77","author":"Jabbari","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib107","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2019.10.012","article-title":"Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes?","volume":"69","author":"Shoeibi","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib109","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200157","article-title":"Structural MRI ratios fail to distinguish progressive supranuclear palsy from Parkinson disease in individual patients","volume":"13","author":"Dewey","year":"2023","journal-title":"Neurol Clin Pract"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/mds.27038","article-title":"Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib111","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.parkreldis.2018.04.005","article-title":"The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism","volume":"54","author":"Mueller","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"10.1016\/j.ncl.2024.12.006_bib112","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","article-title":"Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework","volume":"48","author":"Bischof","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.ncl.2024.12.006_bib113","doi-asserted-by":"crossref","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","article-title":"Cerebrospinal fluid biomarkers in autopsy-confirmed alzheimer disease and frontotemporal lobar degeneration","volume":"98","author":"Mattsson-Carlgren","year":"2022","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib114","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/mds.29322","article-title":"Why therapeutic trials fail in primary tauopathies","volume":"38","author":"Olfati","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2024.12.006_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.694872","article-title":"Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP centers of care","volume":"12","author":"Bluett","year":"2021","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib116","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13543784.2018.1460356","article-title":"Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy","volume":"27","author":"Shoeibi","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ncl.2024.12.006_bib117","first-page":"23","article-title":"Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life","volume":"92","author":"Rebeiz","year":"1967","journal-title":"Trans Am Neurol Assoc"},{"issue":"Pt 5","key":"10.1016\/j.ncl.2024.12.006_bib118","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/brain\/112.5.1171","article-title":"Corticobasal degeneration","volume":"112","author":"Gibb","year":"1989","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib119","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/1531-8249(200003)47:3<374::AID-ANA15>3.0.CO;2-8","article-title":"Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy","volume":"47","author":"Di Maria","year":"2000","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2024.12.006_bib120","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.56.12.1702","article-title":"Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype","volume":"56","author":"Houlden","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/JAD-2010-091615","article-title":"VEGF haplotypes are associated with increased risk to progressive supranuclear palsy and corticobasal syndrome","volume":"21","author":"Borroni","year":"2010","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.ncl.2024.12.006_bib122","doi-asserted-by":"crossref","first-page":"7247","DOI":"10.1038\/ncomms8247","article-title":"Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy","volume":"6","author":"Kouri","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib123","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00401-017-1693-y","article-title":"Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia","volume":"133","author":"Yokoyama","year":"2017","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib124","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2024.12.006_bib125","article-title":"Corticobasal syndrome: are there central or peripheral triggers?","author":"Lenka","year":"2024","journal-title":"Neurology Clin Pract"},{"key":"10.1016\/j.ncl.2024.12.006_bib126","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/bs.irn.2019.10.014","article-title":"Corticobasal degeneration","volume":"149","author":"Saranza","year":"2019","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib127","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad296","article-title":"Clinical course of pathologically confirmed corticobasal degeneration and corticobasal syndrome","volume":"5","author":"Aiba","year":"2023","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib128","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1212\/WNL.0000000000009734","article-title":"Clinical and pathologic features of cognitive-predominant corticobasal degeneration","volume":"95","author":"Sakae","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2024.12.006_bib129","article-title":"CBD diagnostic criteria: exclusions as important as inclusions","author":"Litvan","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatr"},{"issue":"8","key":"10.1016\/j.ncl.2024.12.006_bib130","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/jnnp-2013-307035","article-title":"Validation of the new consensus criteria for the diagnosis of corticobasal degeneration","volume":"85","author":"Alexander","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.26930","article-title":"Evaluating the effect of alzheimer's disease-related biomarker change in corticobasal syndrome and progressive supranuclear palsy","volume":"96","author":"Garcia-Cordero","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2024.12.006_bib132","first-page":"87","article-title":"Corticobasal degeneration","volume":"vol. 149","author":"Saranza","year":"2019"},{"issue":"2","key":"10.1016\/j.ncl.2024.12.006_bib133","first-page":"439","article-title":"Corticobasal degeneration: key emerging issues","volume":"265","author":"Ali","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib134","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00401-016-1618-1","article-title":"[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration","volume":"132","author":"Josephs","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/pn-2020-002797","article-title":"Multiple system atrophy","volume":"23","author":"Goh","year":"2023","journal-title":"Pract Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2024.12.006_bib136","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","article-title":"The natural history of multiple system atrophy: a prospective European cohort study","volume":"12","author":"Wenning","year":"2013","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib137","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-022-00382-6","article-title":"Multiple system atrophy","volume":"8","author":"Poewe","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib138","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10286-015-0279-9","article-title":"Prevalence of REM sleep behavior disorder in multiple system atrophy: a multicenter study and meta-analysis","volume":"25","author":"Palma","year":"2015","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.ncl.2024.12.006_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104996","article-title":"REM sleep behavior disorder (RBD)","volume":"143","author":"Hu","year":"2020","journal-title":"Neurobiol Dis"},{"issue":"5","key":"10.1016\/j.ncl.2024.12.006_bib140","first-page":"1350","article-title":"Multiple system atrophy","volume":"28","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"6","key":"10.1016\/j.ncl.2024.12.006_bib141","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The movement disorder society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.ncl.2024.12.006_bib142","first-page":"1036","article-title":"An update on advances in magnetic resonance imaging of multiple system atrophy","volume":"266","author":"Chelban","year":"2019","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2024.12.006_bib143","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin \u03b1-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2021","journal-title":"JAMA Neurol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861924001014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:18:16Z","timestamp":1762309096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861924001014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":143,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0733861924001014"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.006","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Atypical Parkinsonian Disorders","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}